Presentation at Vator Securities Unicorn Summit
Bio-Works presents at the Vator Securities Unicorn Summit, showcasing its technology and growth strategy to investors.
Investment presentation at BioStock
Bio-Works presents investment case at BioStock, highlighting its technology and growth opportunities in Nordic life sciences.
Bio-Works is now ISO 9001:2015 certified
Bio-Works achieves ISO 9001:2015 certification, demonstrating its commitment to quality management and regulatory compliance.
Bokslutskommuniké Januari – december 2018
Bio-Works publicerar sin bokslutskommuniké för januari–december 2018 med finansiella resultat och viktiga händelser.
Bio-Works increased customer base by 125% during 2018
Bio-Works reports a 125% increase in its customer base during 2018, reflecting strong commercial growth across all key markets.
WorkBeads affimAb launched
Bio-Works launches WorkBeads affimAb, a novel affinity resin designed for the purification of next-generation biological pharmaceuticals.
Bio-Works increases target for the number of new customers 2018
Bio-Works raises its new customer target for 2018, reflecting strong commercial momentum and growing market demand.
Bio-Works forms distinguished Scientific Advisory Board
Bio-Works establishes a Scientific Advisory Board of leading experts to guide its research and product development strategy.
WorkBeads used for full scale production of FDA approved drug
Bio-Works' WorkBeads resins are used in full-scale commercial production of an FDA-approved biopharmaceutical, validating the product's quality and reliability.
Bio-Works opens sales office in USA
Bio-Works opens a US sales office, marking a key step in expanding its presence in the world's largest biopharmaceutical market.
